Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
The patient missed the third dose of Vivotif; Case reference number US-BN-2025-001155 is a spontaneous case initially received from physician via Communication (reference number: USBAV25-1633) on 07-Jul-2025 and concerns a 16-years-old patient of unspecified gender. The patient's medical history and concomitant medication details were not provided. On 01-Jul-2025, the patient took first dose of Vivotif (batch number: unknown) orally, at unknown dose, for unknown indication. On an unspecified date, unknown time after first dose, the patient took second dose of Vivotif (batch number: unknown) orally, at unknown dose. As reported, the patient missed the third dose of Vivotif with the fourth dose scheduled for today (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if patient experienced any adverse event due to Vivotif. No further information provided.; Reporter's Comments: This case concerns a 16-years-old patient of unspecified gender, who received first and second doses of Vivotif vaccine, for an unknown indication. As reported, the patient missed the third dose of Vivotif with the fourth dose scheduled for today, which is considered as ' product dose omission issue'. Product dose omission issue is considered as listed per company convention. At the time of the initial report, it was unknown if patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a 16-years-old patient of unspecified gender, who received first and second doses of Vivotif vaccine, for an unknown indication. As reported, the patient missed the third dose of Vivotif with the fourth dose scheduled for today, which is considered as ' product dose omission issue'. Product dose omission issue is considered as listed per company convention. At the time of the initial report, it was unknown if patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.